Effects of intravenous atrial natriuretic peptide and nitroglycerin on coronary vasodilation and flow velocity determined using 3 T magnetic resonance imaging in patients with nonischemic heart failure

[1]  N. Hagiwara,et al.  Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes , 2013, Heart and Vessels.

[2]  D. Kass,et al.  Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling , 2012, Circulation.

[3]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[4]  F. Fedele,et al.  Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging , 2012, Circulation.

[5]  L. R. Potter,et al.  Guanylyl cyclase structure, function and regulation. , 2011, Cellular signalling.

[6]  C. von Birgelen,et al.  Infarct tissue characteristics of patients with versus without early revascularization for acute myocardial infarction: a contrast enhancement cardiovascular magnetic resonance imaging study , 2011, Journal of Cardiovascular Magnetic Resonance.

[7]  K. Katahira,et al.  Assessment of coronary artery disease using magnetic resonance coronary angiography: a national multicenter trial. , 2010, Journal of the American College of Cardiology.

[8]  S. Kunimoto,et al.  Detection of coronary artery disease by free-breathing, whole heart coronary magnetic resonance angiography: our initial experience , 2009, Heart and Vessels.

[9]  Kan Takeda,et al.  Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography. , 2006, Journal of the American College of Cardiology.

[10]  Bob S. Hu,et al.  Noninvasive assessment of coronary vasodilation using magnetic resonance angiography. , 2005, Journal of the American College of Cardiology.

[11]  Paramate Horkaew,et al.  Intra‐ and interstudy reproducibility of coronary artery diameter measurements in magnetic resonance coronary angiography , 2004, Journal of magnetic resonance imaging : JMRI.

[12]  EikeNagel,et al.  Noninvasive Determination of Coronary Blood Flow Velocity With Cardiovascular Magnetic Resonance in Patients After Stent Deployment , 2003 .

[13]  E. Wellnhofer,et al.  Noninvasive Determination of Coronary Blood Flow Velocity With Cardiovascular Magnetic Resonance in Patients After Stent Deployment , 2003, Circulation.

[14]  René M. Botnar,et al.  Coronary MR angiography clinical applications and potential for imaging coronary artery disease. , 2003, Magnetic resonance imaging clinics of North America.

[15]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[16]  Jeroen J. Bax,et al.  Coronary magnetic resonance angiography: technical developments and clinical applications. , 2003, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[17]  D. Gardner,et al.  N ATRIURETIC P EPTIDES , 1998 .

[18]  M. Currie,et al.  Correlation between vascular and cellular responses to atrial natriuretic peptide and to sodium nitroprusside. , 1994, Life sciences.

[19]  M. Kinoshita,et al.  Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries. , 1993, European journal of pharmacology.

[20]  P. Merlet,et al.  Hemodynamic Response to Intracoronary Infusion of Atrial Natriuretic Factor in Patients with Normal or Altered Left Ventricular function , 1991, Journal of cardiovascular pharmacology.

[21]  A. Takeshita,et al.  Effects of synthetic human atrial natriuretic peptide on the human coronary circulation in subjects with normal coronary arteries. , 1991, Japanese circulation journal.

[22]  F. Cobb,et al.  Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. , 1989, Circulation.

[23]  J. Horowitz,et al.  Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. , 1989, The Journal of pharmacology and experimental therapeutics.

[24]  D. Gardner,et al.  Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. , 1988, The American journal of physiology.

[25]  F. Cobb,et al.  Effects of Atrial Natriuretic Peptide on Proximal Epicardial Coronary Arteries and Coronary Blood Flow in Conscious Dogs , 1987, Circulation research.

[26]  Andrew,et al.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.

[27]  F. Murad,et al.  Cyclic guanosine monophosphate as a mediator of vasodilation. , 1986, The Journal of clinical investigation.

[28]  F. Murad,et al.  Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta. , 1985, European journal of pharmacology.

[29]  F. Murad,et al.  Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. , 1984, The Journal of biological chemistry.

[30]  J. Parker,et al.  Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy. , 1984, The American journal of cardiology.